Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation
Nutrition · 2024-08 · 124 · 112466
DOI: 10.1016/j.nut.2024.112466 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Nutrition, 2024-08. Verfasst von Małgorzata Szlendak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Medical University of Warsaw, Warsaw, Poland. Electronic address: malgorzata.m.szlendak@gmail.com. Hauptthemen laut MEDLINE: Cachexia, Eicosapentaenoic Acid, Neoplasms, Docosahexaenoic Acids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerstwo Edukacji i Nauki.
Abstract (Originalsprache)
Chronic inflammation is a hallmark of cancer cachexia. Polyunsaturated fatty acids (ω-3 PUFAs): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are known to contribute to the reduction of inflammation, preservation of lean body mass and total body weight, and reduction of cancer-related symptoms, such as anorexia or neuropathy. This systematic review aimed to assess whether the ratio of EPA to DHA used in supplementation in cancer patients matters in the context of the resolution of inflammation and reduction of the risk of cachexia. The analysis included 20 randomized clinical trials with acceptable quality identified from the Pubmed/MEDLINE database. The significant results concerning the resolution of inflammation or improvement in nutritional status were the highest in the case of a low EPA/DHA ratio, i.e., 67%, and decreased, reaching 50% and 36% for the moderate and high ratios, respectively. Most results concerning body weight from high and moderate EPA/DHA ratios showed no benefit or were insignificant. A significant benefit in reducing any reported inflammatory markers was seen in the low EPA/DHA ratio subgroup at 63%, in the moderate at 29%, and in the high ratio subgroup at 11%. The greatest benefit in CRP reduction was obtained by patients during chemotherapy. The review questions the anticachectic and anti-inflammatory effect of ω-3 PUFAs supplementation with doses of EPA higher than DHA. A population that particularly benefits from ω-3 PUFAs supplementation are patients undergoing chemotherapy for advanced cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Medical University of Warsaw, Warsaw, Poland. Electronic address: malgorzata.m.szlendak@gmail.com.
- Department of Clinical Nutrition, Department of Oncology Diagnostics, Cardio-Oncology and Palliative Medicine, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Förderung
- Ministerstwo Edukacji i Nauki
Zitieren
APA
Szlendak, M., & Kapała, A. (2024). Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation. Nutrition, 124, 112466. https://doi.org/10.1016/j.nut.2024.112466
Vancouver
Szlendak M, Kapała A. Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation. Nutrition. 2024;124:112466. doi:10.1016/j.nut.2024.112466
BibTeX
@article{Szlendak2024,
author = {Szlendak, Małgorzata and Kapała, Aleksandra},
title = {Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation},
journal = {Nutrition},
year = {2024},
volume = {124},
pages = {112466},
doi = {10.1016/j.nut.2024.112466}
}
EUVIMED